According to the last Half Yearly Report -
"The completion of enrolment in the Phase 2 HCV 3-month dosing trial is a key milestone for the Company. This trial is important as it will provide key data for future dosing regimens with BIT225, as well as important longer-term dosing safety data. It will also provide additional efficacy data against HCV genotypes 1 and 3. It is anticipated that preliminary data, from the end of BIT225 dosing time point, will be available in the second quarter of 2015, with additional data from later time points available in the second half of 2015."
It was earlier reported to be late first quarter 2015, ie around now.
According to the last Half Yearly Report - "The completion of...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
0.002(3.70%) |
Mkt cap ! $50.52M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.6¢ | 5.4¢ | $17.98K | 324.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 195214 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 77240 | 4 |
View Market Depth
| Last trade - 14.35pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.6¢ |
Change
0.002 ( 3.70 %) |
||||
| Open | High | Low | Volume | ||
| 5.6¢ | 5.6¢ | 5.5¢ | 112116 | ||
| Last updated 14.35pm 03/06/2024 ? | |||||
| BIT (ASX) Chart |